FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini, Mailis Maes, Gwilym James Webb et al. · Nature · 2022
. However, the mechanisms that control the expression of ACE2 remain unclear. Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2 transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that UDCA reduces the expression of ACE2 in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes after SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of recipients of liver transplants. In conclusion, we show that FXR has a role in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the way for future clinical trials.
Cited by 293 works. doi:10.1038/s41586-022-05594-0 Open-access PDF
Authors
- Teresa Brevini
- Mailis Maes
- Gwilym James Webb
- Binu V. John
- Claudia Daniela Fuchs
- Gustav Buescher
- Lu Wang
- C. Griffiths
- Marnie L. Brown
- Pehuén Pereyra-Gerber
- William Gelson
- Stephanie Emma Brown
- Scott Dillon
- Daniele Muraro
- Joanne Sharp
- Megan Neary
- Helen Box
- Lee M. Tatham
- James P. Stewart
References
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- Dexamethasone in Hospitalized Patients with Covid-19
- Remdesivir for the Treatment of Covid-19 — Final Report
- Extrapulmonary manifestations of COVID-19
- SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- Immunology of COVID-19: Current State of the Science
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- SARS-CoV-2 evolution during treatment of chronic infection
- A randomized trial of normothermic preservation in liver transplantation